""I'm a bit overwhelmed and so incredibly proud of everyone who helped get us here. 10 years ago Anthony George and I spun-out SAGA Diagnostics, and today it enters a definitive merger agreement with Foundation Medicine (Roche). This means ultrasensitive ctDNA monitoring can now reach thousands of cancer patients around the world.""
""Our mission at SAGA is to intercept cancer early when patients are most treatable and curable. Foundation Medicine's commercial scale and innovation accelerates our ability to bring this unique MRD platform to more patients worldwide.""
SAGA Diagnostics, a biotechnology company from Lund, is set to be acquired by Foundation Medicine for up to €504 million. This acquisition highlights the increasing demand for precision diagnostics and liquid biopsy solutions. SAGA has developed technology that detects cancer through DNA analysis from blood samples, allowing for sensitive detection of residual disease. Their product, Pathlight™, has achieved clinical validation and commercial success, positioning the company as a leader in the liquid biopsy market, which aims to improve cancer treatment outcomes through early detection.
Read at resund Startups
Unable to calculate read time
Collection
[
|
...
]